Journal
CLINICAL & TRANSLATIONAL ONCOLOGY
Volume 10, Issue 2, Pages 73-77Publisher
SPRINGER INTERNATIONAL PUBLISHING AG
DOI: 10.1007/s12094-008-0159-z
Keywords
EGFr; gliomas; tyrosine kinase; PTEN; AKT
Categories
Ask authors/readers for more resources
High-grade gliomas are the most common primary malignant brain tumours. Surgery, radiotherapy and chemotherapy are the cornerstone of actual treatment. In spite of large therapeutic efforts, overall survival is still poor. New molecular data allow a new molecular classification for high-grade gliomas and open a therapeutic window for targeted therapy. Molecular diagnostic tools may provide a basis for receptor-based therapies and enough information to personalise future treatments. In this regard, epidermal growth factor receptor (EGFR) is a target that will play a critical role in the management of glioma patients. This review summarises basic and preclinical data that support future use of therapies against EGFR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available